Folic Acid and Vitamin B12 Increase Risk of Cancer in Patients with Heart Disease(11/19/2009) Researchers from Norway have reported that folic acid and B12 supplements in patients with ischemic heart disease increase the risk of cancer and all-cause mortality. The details of this study appeared in the November 18, 2009 issue of the Journal of the American Medical Society.
Physical Activity May Reduce Risk of Developing Prostate Cancer(11/18/2009) Researchers from U.S. and European medical centers have reported that not sitting during work, occupational activity, walking, and biking can reduce the risk of developing prostate cancer. The details of this study were published early online on October 27, 2009 in the British Journal of Cancer.
Dutasteride Effective in Reducing Risk of Prostate Cancer in High-risk Men(10/8/2009) Researchers involved in the international Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, have reported that dutasteride, a 5-alpha-reductase inhibitor that inhibits conversion of testosterone into dihydrotestosterone, is effective in reducing the risk of biopsy-proven prostate cancer in men with an elevated prostate specific antigen (PSA) with negative prostate biopsies. The details of this study were reported at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24.
Trichomonas Vaginalis Infection Linked to Aggressive Prostate Cancer(9/15/2009) Researchers affiliated with the Physicians’ Health Study have reported that men who are seropositive for Trichomonas vaginalis are at risk for more advanced prostate cancer than men who are seronegative. The details of this study appeared early online in the Journal of theNational Cancer Institute on September 8, 2009.
Study Explores Overdiagnosis of Prostate Cancer(9/14/2009) Researchers from Dartmouth and the University of Connecticut have reported that for every man who benefits from prostate cancer screening, many more are diagnosed and treated unnecessarily. The extent of this “overdiagnosis” of prostate cancer was explored in a study published in the Journal of the National Cancer Institutein an early online publication on August 31, 2009.
High-dose Mixed Proton and Photon Radiotherapy May Improve Treatment of Prostate Cancer(11/13/2009) Researchers affiliated with the Proton Radiation Oncology Group (PROG)/American College of Radiology (ACR) 95-09 study have reported that mixed proton and photon radiotherapy improves outcomes of patients with low- and intermediate-risk prostate cancer. The details of this randomized trial were presented at the 2009 meeting of the American Society of Radiation Therapy and Oncology (ASTRO) in the first week of November.
Radiotherapy and Hormonal Therapy Effective for Men with Prostate Cancer Failing Surgery(11/10/2009) Researchers from the Mayo Clinic have reported that relapse-free survival was over 90% in patients treated with salvage radiotherapy (RT) plus two years of androgen deprivation therapy (ADT) for post-prostatectomy relapse. The details of this study were presented at the 2009 meeting of the American Society of Therapeutic Radiology and Oncology in the first week in November, 2009.
Neoadjuvant Taxotere® and ADT Well Tolerated in High-risk Prostate Cancer(10/27/2009) Researchers from Spain have reported that neoadjuvant Taxotere® (docetaxel) and androgen deprivation therapy (ADT) was well tolerated and associated with a 6% pathological complete response (pCR) rate and a 6% near pCR rate in men with high-risk prostate cancer. The details of this study appeared in the October 13, 2009 issue of the British Journal of Cancer.
Relative Effectiveness of Minimally Invasive Prostatectomy vs Open Prostatectomy Debated(10/15/2009) Researchers from Harvard University have reported that men undergoing minimally invasive radical prostatectomy (MIRP) have “a shorter hospital stay, fewer respiratory and miscellaneous surgical complications and strictures, and similar postoperative use of additional cancer therapies but experienced more genitourinary complications, incontinence, and erectile dysfunction” than men undergoing conventional open retropubic prostatectomy (RRP). The details of this study appeared in the October 14, 2009 issue of the Journal of the AmericanAssociation.
Radiotherapy plus Adjuvant Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: Ten-year Results(10/8/2009) Researchers affiliated with European Organization for Research for the Treatment of Cancer (EORTC) trial 22863 have reported that three years of adjuvant androgen deprivation therapy (ADT) in men with locally advanced prostate cancer receiving radiotherapy improves survival without late cardiovascular toxicity with a 10-year follow-up. The details of this analysis were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24.
Radiotherapy and Hormonal Therapy Effective for Men with Prostate Cancer Failing Surgery(11/10/2009) Researchers from the Mayo Clinic have reported that relapse-free survival was over 90% in patients treated with salvage radiotherapy (RT) plus two years of androgen deprivation therapy (ADT) for post-prostatectomy relapse. The details of this study were presented at the 2009 meeting of the American Society of Therapeutic Radiology and Oncology in the first week in November, 2009.
Neoadjuvant Taxotere® and ADT Well Tolerated in High-risk Prostate Cancer(10/27/2009) Researchers from Spain have reported that neoadjuvant Taxotere® (docetaxel) and androgen deprivation therapy (ADT) was well tolerated and associated with a 6% pathological complete response (pCR) rate and a 6% near pCR rate in men with high-risk prostate cancer. The details of this study appeared in the October 13, 2009 issue of the British Journal of Cancer.
Radiotherapy plus Adjuvant Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: Ten-year Results(10/8/2009) Researchers affiliated with European Organization for Research for the Treatment of Cancer (EORTC) trial 22863 have reported that three years of adjuvant androgen deprivation therapy (ADT) in men with locally advanced prostate cancer receiving radiotherapy improves survival without late cardiovascular toxicity with a 10-year follow-up. The details of this analysis were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24.
Androgen Deprivation Therapy Increases Risk of Heart Disease in Prostate Cancer(10/7/2009) Researchers from Sweden have reported that androgen deprivation therapy (ADT) in men with advanced prostate cancer may lead to an increased risk of heart disease. The details of this study were presented September 22, 2009 at Europe’s largest cancer congress, ECCO 15-ESMO 34, in Berlin.
Prevalent Vertebral Fractures in Men Receiving ADT for Prostate Cancer Shorten Overall Survival(9/23/2009) Researchers involved in a multicenter international study evaluating denosumab for prevention of new vertebral fractures in patients with prostate cancer receiving androgen deprivation therapy (ADT) have reported that men with prevalent vertebral fractures (PVFs) at baseline had a decreased survival compared with men without such fractures. The details of this study were presented at the Joint ECCO 15-34th ESMO Multidisciplinary Congress in Berlin September 20-24, 2009.
Radium-223 (Alpharadin®) Effective Palliation for Prostate Cancer Metastatic to Bone(10/9/2009) Researchers involved in three Phase II European multicenter studies have reported that Alpharadin® (radium-223), an alpha emitter, is effective and well tolerated for the treatment of men with hormone refractory prostate cancer (HRPC) with metastatic bone lesions. The details of these studies were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24 2009.
Radiotherapy plus Adjuvant Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: Ten-year Results(10/8/2009) Researchers affiliated with European Organization for Research for the Treatment of Cancer (EORTC) trial 22863 have reported that three years of adjuvant androgen deprivation therapy (ADT) in men with locally advanced prostate cancer receiving radiotherapy improves survival without late cardiovascular toxicity with a 10-year follow-up. The details of this analysis were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24.
Androgen Deprivation Therapy Increases Risk of Heart Disease in Prostate Cancer(10/7/2009) Researchers from Sweden have reported that androgen deprivation therapy (ADT) in men with advanced prostate cancer may lead to an increased risk of heart disease. The details of this study were presented September 22, 2009 at Europe’s largest cancer congress, ECCO 15-ESMO 34, in Berlin.
Bonefos® Improves Survival in Metastatic Prostate Cancer(8/27/2009) Researchers from the UK have reported that Bonefos® (sodium clodronate) reduces the risk of death by 23% in men with metastatic prostate cancer. The details of this study appeared in an early online publication in The Lancet Oncologyon August 11, 2009.
ASCO 2009: Phase I-II Results of New Bcl-2 Inhibitor, AT-101(8/5/2009) At the 2009 meeting of the American Society of Clinical Oncology (ASCO) there were several preclinical and Phase I-II clinical presentations suggesting activity for a new inhibitor of the Bcl-2 family of proteins (Bcl-2, Bcl-xL, Mel-1, Bcl-W), AT-109, developed by Ascenta Therapeutics.
New Oral Agent, Tasquinimod, May Have Activity in Prostate Cancer(10/26/2009) Researchers from Sweden have reported that tasquinimod, an oral analog of linomide, may have significant activity in men with hormone-refractory prostate cancer (HRPC). The details of this study appeared in the October 13, 2009 issue of the British Journal of Cancer.
Radium-223 (Alpharadin®) Effective Palliation for Prostate Cancer Metastatic to Bone(10/9/2009) Researchers involved in three Phase II European multicenter studies have reported that Alpharadin® (radium-223), an alpha emitter, is effective and well tolerated for the treatment of men with hormone refractory prostate cancer (HRPC) with metastatic bone lesions. The details of these studies were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24 2009.
More Detailed Results for Provenge® in Prostate Cancer Presented(5/1/2009) According to the results of the Phase III IMPACT trial, treatment with Provenge® (sipuleucel-T), an investigational immunotherapy, improved overall survival by 4.1 months among men with metastatic, androgen-independent prostate cancer. These results were presented at the 2009 annual meeting of the American Urological Association.
Avastin® May have Activity in Hormone-refractory Prostate Cancer(11/7/2008) Researchers from Italy have reported that Avastin® (bevacizumab) plus docetaxel (Taxotere®) may have activity in patients with hormone-refractory prostate cancer (HRPC) who had previously been treated with Taxotere. The details of this study were reported in the November 2008 issue of European Urology.
Body Weight and C-Peptide Levels Associated with Risk of Dying from Prostate Cancer(10/22/2008) Researchers from Harvard University have reported that excess body weight coupled with a high C-peptide level among men with prostate cancer is associated with an increased risk of death from the disease. These results were recently published in an early online version of the Lancet Oncology on October 3, 2008.
Patient Home
